Please login to the form below

Not currently logged in
Email:
Password:

Celgene hires Thomas Moriarty to lead legal strategy

Joins as general counsel and corporate secretary from Medco Health Solutions

Thomas Moriarty has joined Celgene as general counsel and corporate secretary, a role that will see him  lead global legal strategy at the US biopharma and serve on its management committee.

“Tom Moriarty brings a wealth of experience in global strategic and legal healthcare management,” said Robert Hugin, chair and CEO of Celgene.

“His extensive legal background, as well as his significant leadership experience will provide new insight and valuable perspective on the increasingly complex global healthcare environment.”

This background includes 12 years at Medco Health Solutions from 2000 to 2012, during which he spent his final four years as general counsel and corporate secretary.

Moriarty held several other legal, regulatory, public policy and corporate governance positions at Medco including president, global pharmaceutical strategies; senior VP, pharma strategies and solutions; and senior VP of business development.

Prior to joining Medco, he served as assistant general counsel - pharma and North America for Merial Limited, a Merck & Co and Aventis Company, and as senior attorney for Merck.

9th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics